Artwork

Content provided by Sam Parnell & Ivanna Rosendal, Sam Parnell, and Ivanna Rosendal. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Sam Parnell & Ivanna Rosendal, Sam Parnell, and Ivanna Rosendal or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
Player FM - Podcast App
Go offline with the Player FM app!

Ravi Samavedam: On demand clean rooms for clinical trial supply

34:23
 
Share
 

Manage episode 382347589 series 3526489
Content provided by Sam Parnell & Ivanna Rosendal, Sam Parnell, and Ivanna Rosendal. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Sam Parnell & Ivanna Rosendal, Sam Parnell, and Ivanna Rosendal or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.

This week we speak to Ravi Samavedam, Chief Innovation Officer for Azzur Group, about how on demand clean rooms can transform the business model for biotechs.

We start out by exploring what the standard two choices biotech’s typically have for clinical trial manufacturing:

  1. Building their own infrastructure
  2. Outsourcing to a contract manufacturing organization

Both options have pros and cons. Many of the cons can be mitigated by the third option that Ravi suggests - renting the infrastructure. This enables the biotech to keep control with the manufacturing process and keep experimenting, while avoiding the upfront investment in the infrastructure that may change.

We also dive into the compliance of the facilities, and how outsourcing the quality assurance of the facilities themselves can allow the biotech’s to focus on the production process and science.

Even though the clean rooms for the different companies are in the same facilities, there is no exchange of air or supplies between the rooms - and also limited exchange of ideas between the individual production lines due to confidentiality.

As a small biotech it is easy to fall into the trap of going overboard with GMP regulation adherence. And how GMP stamina is necessary to know where to draw the line of sufficient quality.

Guest:

Ravi Samavedam

https://www.linkedin.com/in/ravi-samavedam-65a8345/

Azzur

https://azzur.com/

________
Reach out to Sam Parnell and Ivanna Rosendal
Join the conversation on our LinkedIn page

  continue reading

64 episodes

Artwork
iconShare
 
Manage episode 382347589 series 3526489
Content provided by Sam Parnell & Ivanna Rosendal, Sam Parnell, and Ivanna Rosendal. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Sam Parnell & Ivanna Rosendal, Sam Parnell, and Ivanna Rosendal or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.

This week we speak to Ravi Samavedam, Chief Innovation Officer for Azzur Group, about how on demand clean rooms can transform the business model for biotechs.

We start out by exploring what the standard two choices biotech’s typically have for clinical trial manufacturing:

  1. Building their own infrastructure
  2. Outsourcing to a contract manufacturing organization

Both options have pros and cons. Many of the cons can be mitigated by the third option that Ravi suggests - renting the infrastructure. This enables the biotech to keep control with the manufacturing process and keep experimenting, while avoiding the upfront investment in the infrastructure that may change.

We also dive into the compliance of the facilities, and how outsourcing the quality assurance of the facilities themselves can allow the biotech’s to focus on the production process and science.

Even though the clean rooms for the different companies are in the same facilities, there is no exchange of air or supplies between the rooms - and also limited exchange of ideas between the individual production lines due to confidentiality.

As a small biotech it is easy to fall into the trap of going overboard with GMP regulation adherence. And how GMP stamina is necessary to know where to draw the line of sufficient quality.

Guest:

Ravi Samavedam

https://www.linkedin.com/in/ravi-samavedam-65a8345/

Azzur

https://azzur.com/

________
Reach out to Sam Parnell and Ivanna Rosendal
Join the conversation on our LinkedIn page

  continue reading

64 episodes

All episodes

×
 
Loading …

Welcome to Player FM!

Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.

 

Quick Reference Guide